Brief: Lyell Announces FDA Clearance Of IND For LYL132
24/01/2022 16:59
Jan 24 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA ANNOUNCES FDA CLEARANCE OF IND FOR
LYL132, A
T-CELL RECEPTOR THERAPY FOR SOLID TUMORS BEING DEVELOPED IN
COLLABORATION WITH GSK
* LYELL IMMUNOPHARMA INC - CO WILL MANUFACTURE LYL132 IN ITS
LYFE
MANUFACTURING CENTER AND GSK WILL CONDUCT PHASE 1 TRIAL
Source text for Eikon: ID:nGNXlTfM9
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma